Trends in incidence and mortality of prostate cancer in Ningbo City from 2011 to 2023
ZHANG Qun1, WANG Yong1, CHEN Jieping1, BAO Kaifang1, FENG Yueyi1, Wang Xiaoli2
1. Ningbo Center for Disease Control and Prevention, Ningbo, Zhejiang 315010, China; 2. Ningbo College of Health Sciences, Ningbo, Zhejiang 315800, China
Abstract：Objective To analyze the trends in incidence and mortality of prostate cancer in Ningbo City, Zhejiang Province, so as to provide insights into the prevention and control of prostate cancer. Methods Data of the incidence and mortality of prostate cancer in Ningbo City from 2011 to 2023 were collected through Ningbo Chronic Disease Collaborative Management System. The incidence and mortality of prostate cancer were calculated and standardized by the data from the sixth national population census in 2010 and the Segi's world standard population in 1960. The trends in incidence and mortality of prostate cancer were evaluated using average annual percent change (AAPC). Results A total of 15 411 cases of prostate cancer were reported in Ningbo City from 2011 to 2023, and the crude incidence, Chinese-standardized incidence and world-standardized incidence were 39.62/105, 22.18/105 and 16.49/105, respectively, showing upward trends (AAPC=14.782%, 10.390% and 10.608%, all P<0.05). The Chinese-standardized incidence of prostate cancer was higher in urban areas than in rural areas, and both showed upward trends (25.14/105 vs. 19.44/105; AAPC=9.057% and 14.272%, both P<0.05). The crude incidence of prostate cancer in the groups aged 50-<60 years, 60-<70 years, 70-<80 years and ≥80 years showed upward trends (AAPC=11.657%, 14.031%, 10.734% and 5.300%, all P<0.05). A total of 3 739 deaths were reported, and the crude mortality, Chinese-standardized mortality and world-standardized mortality were 9.66/105, 5.23/105 and 3.71/105, respectively, showing upward trends (AAPC=8.458%, 3.620% and 3.602%, all P<0.05). The Chinese-standardized mortality of prostate cancer was higher in urban areas than in rural areas, and both showed upward trends (5.35/105 vs. 5.13/105; AAPC=3.183% and 3.962%, both P<0.05). The crude mortality of prostate cancer the groups ageds ≥80 years showed an upward trend (AAPC=7.482%, P<0.05). Conclusions From 2011 to 2023, the incidence and mortality of prostate cancer in Ningbo City showed upward trends. Special attention should be paid to urban residents, and prostate cancer screening should be strengthened among males aged 50 years and older.
章群, 王永, 陈洁平, 包凯芳, 冯玥溢, 王小丽. 2011—2023年宁波市前列腺癌发病和死亡趋势分析[J]. 预防医学, 2025, 37(1): 46-50.
ZHANG Qun, WANG Yong, CHEN Jieping, BAO Kaifang, FENG Yueyi, Wang Xiaoli. Trends in incidence and mortality of prostate cancer in Ningbo City from 2011 to 2023. Preventive Medicine, 2025, 37(1): 46-50.
[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263. [2] 张希,杨雷,刘硕,等.2022年全球恶性肿瘤统计报告解读[J].中华肿瘤杂志,2024,46(7):710-721. ZHANG X,YANG L,LIU S,et al.Interpretation on the report of global cancer statistics 2022[J].Chin J Oncol,2024,46(7):710-721.(in Chinese) [3] JAMES N D,TANNOCK I,N'DOW J,et al.The Lancet Commission on prostate cancer:planning for the surge in cases[J].Lancet,2024,403(10437):1683-1722. [4] 李辉章,杜灵彬.Joinpoint回归模型在肿瘤流行病学时间趋势分析中的应用[J].中华预防医学杂志,2020,54(8):908-912. LI H Z,DU L B.Application of Joinpoint regression model in cancer epidemiological time trend analysis[J].Chin J Prev Med,2020,54(8):908-912.(in Chinese) [5] HAN B F,ZHENG R S,ZENG H M,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53. [6] 朱洪挺,胡云卿,李辉章,等.2010—2014年浙江省肿瘤登记地区前列腺癌发病与死亡分析[J].中国肿瘤,2019,28(2):110-114. ZHU H T,HU Y Q,LI H Z,et al.Incidence and mortality of prostate cancer in Zhejiang cancer registration areas,2010-2014[J].Chin Cancer,2019,28(2):110-114.(in Chinese) [7] 韩苏军,刘飞,邢念增.1988—2015年中国肿瘤登记地区前列腺癌发病趋势分析[J].中华泌尿外科杂志,2022,43(1):51-55. HAN S J,LIU F,XING N Z.Trend analysis of the incidence of prostate cancer in cancer registration areas of China between 1988 and 2015[J].Chin J Urol,2022,43(1):51-55.(in Chinese) [8] 刘硕,王硕,李慧超,等.2000—2017年北京市前列腺癌发病和死亡流行趋势及发病年龄变化特征分析[J].中国肿瘤,2021,30(7):495-505. LIU S,WANG S,LI H C,et al.Analysis on the trends of incidence,mortality and characteristics of age of onset for prostate cancer in Beijing,2000-2017[J].Chin Cancer,2021,30(7):495-505.(in Chinese) [9] 赵俊峰,何丽华,李为翊,等.2002—2019年黄浦区前列腺癌发病和死亡趋势[J].预防医学,2024,36(10):878-881,886. ZHAO J F,HE L H,LI W Y,et al.Trends in incidence and mortality of prostate cancer in Huangpu District from 2002 to 2019[J].China Prev Med J,2024,36(10):878-881,886.(in Chinese) [10] 王永,应焱燕,陈洁平,等.2002—2022年宁波市恶性肿瘤死亡趋势分析[J].预防医学,2023,35(6):496-505. WANG Y,YING Y Y,CHEN J P,et al.Trends in mortality of malignant tumors in Ningbo City from 2002 to 2022[J].China Prev Med J,2023,35(6):496-505.(in Chinese) [11] 郑利伟,宋灵敏,王钢,等.基层医院基于医共体模式下前列腺癌筛查模式的初步探索[J].中华泌尿外科杂志,2024,45(6):416-419. ZHENG L W,SONG L M,WANG G,et al.Preliminary exploration of prostate cancer screening mode based on the medical community model in primary hospitals[J].Chin J Urol,2024,45(6):416-419.(in Chinese) [12] 张美,黄薇羚,童露瑶,等.代谢综合征及其组分与前列腺癌发病风险的关系[J].现代肿瘤医学,2023,31(16):3070-3075. ZHANG M,HUANG W L,TONG L Y,et al.Relationship between metabolic syndrome and its components and the risk of prostate cancer[J].J Mod Oncol,2023,31(16):3070-3075.(in Chinese) [13] HUANG J Q,WEINSTEIN S J,MOORE S C,et al.Pre-diagnostic serum metabolomic profiling of prostate cancer survival[J].J Gerontol A Biol Sci Med Sci,2019,74(6):853-859. [14] 龚杨明,彭鹏,吴春晓.2016年上海市前列腺癌发病和死亡情况与2002—2016年变化趋势分析[J].肿瘤,2023,43(4):297-396. GONG Y M,PENG P,WU C X.Analysis on prostate cancer incidence and mortality in Shanghai 2016 and trends of 2002-2016[J].Tumor,2023,43(4):297-396.(in Chinese) [15] 中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组.前列腺癌筛查中国专家共识(2021年版)[J].中国癌症杂志2021,31(5):435-440. Prostate Cancer Study Group of the Chinese Anti-Cancer Association Urological and Male Reproductive System Tumors Committee.Chinese expert consensus on prostate cancer screening(2021 edition)[J].China Oncol,2021,31(5):435-440.(in Chinese)
